Answers are grounded in this paper and cite their sources.
Observational study reveals endothelial cell injury from venetoclax and azacitidine, indicating treatment-related niche damage in bone marrow.
In this issue of Blood, Ngo et al 1 identify selective injury to sinusoidal endothelial cells caused by venetoclax and azacitidine, revealing a therapyassociated mechanism that links bone marrow (BM) niche damage to impaired hematopoietic recovery.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: